Immunotherapy

The Mass General Cancer Center is committed to understanding the mechanisms by which the immune system works to kill cancer.
Electron microscope image of CAR T-cell interacting with tumor cell. Image courtesy of Maus lab.
Electron microscope image of CAR T-cell interacting with tumor cell. Image courtesy of Maus lab.
Electron microscope image of CAR T-cell interacting with tumor cell. Image courtesy of Maus lab.

Progress in Immunotherapy

Thanks to the hard work of researchers, we're getting smarter about cancer. Right now, we're finding ways to use the body's own immune system to manipulate genes to solve cancer's puzzle.

Learn more about car t-cell therapies.

CAR T-Cell Therapies

Mass General Cancer Center is an authorized treatment center for FDA approved CAR T-cell therapies for adult patients with lymphoma and adult patients with multiple myeloma.

Learn more about the Center for Cancer Immunology.

Center for Cancer Immunology

The Center for Cancer Immunology’s investigators are working to expand the use of immunotherapy, a revolutionary approach to cancer therapy.

Learn more about the Cellular Immunotherapy program.

Cellular Immunotherapy Program

The mission of the Cellular Immunotherapy Program is to invent, develop, administer, and understand engineered immune effector cells.

Severe Immunotherapy Complications Service

The Severe Immunotherapy Complications Service and Clinical-Translational Research Effort Program is working to address the urgent need to understand how and why immune-related adverse events occur.

Learn more
1 of 1

What is Immunotherapy?

Immunotherapy is a type of cancer treatment that uses the body’s immune system to find and attack cancer cells.

Learn more

Noopur Raje, MD, Marcela Maus, MD, PhD and Matthew Frigault, MD discuss the power and evolution of immune therapies, specifically, CAR T-Cell therapy in treating cancer.

Billy Costa talks with Dr. Matt Frigault and oncology social worker Lauren DeMarco to learn more about the latest in CAR- T-cell therapies and what it all means for patients.

Mass General Cancer Center's Dr. Nir Hacohen sits down with Kiss 108's Billy Costa to discuss a researchers perspective of immuno-oncology and how it has impacted patients.

Dr. Justin Gainor summarizes immunotherapy and explains why people should know about these therapies. This video was recorded on May 17, 2019 at the Annual Advances in Cancer Immunotherapy CME Course.

In this presentation from July 8, 2021, Dr. Kerry Reynolds provides an immunotherapy overview. She also discusses the urgent need to understand how and why immune-related adverse events occur and how to best manage them.

Billy Costa of Kiss 108 Radio sits down with Dr. Kerry Reynolds and Dr. Chloe Villani to learn about the incredible team dynamic between research and clinical practice for patients at the Mass General Cancer Center.

Kiss 108 FM’s Billy Costa talks with four experts from the Mass General Cancer Center to learn about what CAR T-cell therapy is and what impact it has on both patients and the medical community.

Meet two researchers at the Mass General Cancer Center who are activating the human immune system to target cancer within the body, Justin Gainor, MD and Nir Hacohen, PhD.

1 of 8

Immune therapy takes a "BiTE" out of brain cancer

A method combining two distinct immune system-based treatments may help to improve outcomes for patients with glioblastomas and other solid tumors.

Learn more
Marcela Maus (left), Bryan Choi (center) and Xiaoling Yu (right)

A Novel CAR T-Cell Therapy for Multiple Myeloma

In this new study published in NEJM, Noopur Raje, MD et al. report the initial toxicity profile of a BCMA-directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma.

Learn more
A Novel CAR T-Cell Therapy for Multiple Myeloma

Dr. Ryan Sullivan on Immunotherapy Approaches in Melanoma

Ryan J. Sullivan, MD, discusses treatment approaches with immunotherapy for patients with melanoma.

Learn more

Beating Resistance to Immunotherapy in Metastatic Melanoma

In this article and companion podcast, learn how Dr. Nir Hacohen’s lab works to understand the mechanisms underlying resistance to immune checkpoint blockade therapy in metastatic melanoma, and how the lab is setting the ground work for two potential new therapies.

Learn more
Nir Hacohen, PhD
1 of 4

Our goal is to understand how immune responses against tumors are initiated, maintained and evaded, with the hope of improving the ability of the immune system to eradicate cancer.

Nir Hacohen, PhD
Director, Center for Cancer Immunology, Mass General Cancer Center

Contact the Cancer Center

Contact the Mass General Cancer Center to make an appointment or learn more about our programs.

Request an appointmentClinical trials617-726-5130